Nasus Pharma Announces Closing of Initial Public Offering
The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate purposes, including working capital, and capital expenditures.
Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC acted as Joint Bookrunners for the offering.
A registration statement on Form F-1 (File No. 333-288582) (the 'Registration Statement') relating to the initial public offering was filed with the Securities and Exchange Commission ('SEC') and declared effective by the SEC on August 12, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities referred to herein nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering was made only by means of a prospectus forming a part of the Registration Statement. A copy of the final prospectus relating to this offering has been filed with the SEC and copies of the final prospectus can be obtained by contacting Laidlaw & Company (UK) Ltd., 521 Fifth Ave, 12th Floor, New York, NY 10075, or by calling 212-953-4900 or by e-mailing syndicate@laidlawltd.com.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal ('PBI') technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.
Forward Looking Statements
This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: statements related to the expected use of proceeds from the Company's initial public offering. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' "will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the final prospectus related to the initial public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Contactinfo@nasuspharma.comNasus Pharma Ltd. Israelhttps://www.nasuspharma.com
Investor ContactMike MoyerLifeSci Advisors+1-617-308-4306mmoyer@lifesciadvisors.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Engineering service firm Legence files for US IPO
(Reuters) -Engineering and maintenance service provider Legence said on Friday it had filed for an initial public offering in the United States. The U.S. IPO market has seen a resurgence in activity with a flurry of companies coming forward to list their shares to tap growing investor confidence, after a slowdown in April due to trade policy changes. Shares of cryptocurrency exchange Bullish more than doubled in their New York debut earlier in the week. Goldman Sachs and Jefferies are the lead book-running managers for the offering. The company will list its shares on Nasdaq under the ticker symbol "LGN". Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Tariffs, Sales Slump Hit Deere, But Analysts See Greener Pastures Ahead
On Thursday, Deere & Company (NYSE:DE) shares tumbled after the agricultural equipment giant posted mixed third-quarter results and trimmed its full-year profit forecast, highlighting persistent headwinds from declining sales, tariffs, and cautious customer demand. The heavy machinery maker reported earnings per share of $4.75, beating the consensus of $4.67. It reported a 9% decline in quarterly sales to $12.02 billion, beating the consensus of $10.31 billion. Production and precision agriculture sales decreased 16% for the quarter to $4.27 billion due to lower shipment volumes and unfavorable price realization. Operating profit slumped 50% to $580 million primarily due to lower shipment volumes/sales narrowed its fiscal 2025 net income guidance to between $4.75 billion and $5.25 billion, compared to its previous forecast of $4.75 billion to $5.50 billion, citing that customers remain cautious amid ongoing uncertainty. Truist Securities said Deere noted some green shoots, including better-than-expected retail sales for tractors in Europe, earthmoving and forestry were positive after several quarters of flat to declining growth, and improving demand in North America turf and compact equipment. Deere projects North American sprayer sales to fall 20% in 2026 based on early orders but views this as not reflective of overall market demand, noting sprayers are only one year into a downturn versus two years for tractors and combines. Truist's Jamie Cook sees 2025 as the EPS trough, with potential upside from production aligned with retail demand, stronger pricing, tariff management, and cost efficiencies, even if overall retail demand remains flat. Truist updated fiscal 2025, 2026, and 2027 earnings per share estimates to $18.30, $21.85, and $27.90, respectively (from $18.55, $24.20, and $30.00, respectively), resulting in a price forecast update from $619 to $602, with an unchanged Buy rating. Analyst Jamie Cook sees greener pastures ahead for Deere & Company, calling it one of the best-managed names in the industrial machinery space, underpinned by a growing technology platform and a resilient earnings stream. Cook notes that Deere has steadily improved through-cycle margins, returns, and cash flow, positioning it to outpace sector peers. According to Cook, Deere's performance in the current farm equipment downturn demonstrates that its earnings and margins are structurally higher than in past cycles, and the company remains on track to meet its 2030 through-cycle margin target of 20%. She projects that 2025 will likely mark the bottom of the farm equipment cycle, with a potential upturn in 2026. Cook also believes the market often underestimates Deere's operating leverage during cyclical recoveries. Price Action: DE stock is trading higher by 1.64% to $486.67 at last check Friday. Read Next:Image via Shutterstock Latest Ratings for DE Date Firm Action From To Mar 2022 Wells Fargo Initiates Coverage On Overweight Feb 2022 Oppenheimer Maintains Outperform Feb 2022 JP Morgan Maintains Underweight View More Analyst Ratings for DE View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? DEERE (DE): Free Stock Analysis Report This article Tariffs, Sales Slump Hit Deere, But Analysts See Greener Pastures Ahead originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Is NuScale Power a buy after recent volatility?
Key Points NuScale Power is a money losing nuclear power upstart. The company is working to build small scale modular nuclear reactors. NuScale Power is making solid progress, but there is still a lot of uncertainty to consider. 10 stocks we like better than NuScale Power › Shares of NuScale Power (NYSE: SMR) have been as low as roughly $7 a share over the past 52 weeks. They have risen as high as $51 or so. And in between those two extremes there was a nearly 58% drawdown, even though the stock is up a whopping 400% over the past year. That's a lot of volatility! Clearly this stock is only appropriate for more aggressive investors, but is it a buy today for even that group? Here's some facts to consider. What does NuScale Power do? Most of NuScale Power's revenues today come from consulting work for Fluor, a large construction company. Fluor also happens to be a large investor in NuScale Power. The consultation services that NuScale is offering relate to a project being considered by RoPower, a Romanian power company. And this all ties back to NuScale because RoPower is lined up to be the first customer for NuScale Power's small modular nuclear reactors (SMRs). Manufacturing SMRs is what NuScale Power is really attempting to do. It is an interesting technology that would, effectively, take existing nuclear power plant technology and scale it down. It's a huge opportunity. SMRs would be made in a factory setting, making them easier and less expensive to build. Moreover, they would incorporate the most modern safety approaches, reducing risk. And they would be small enough to be easily moved around and placed where they were needed, including relatively close to population centers. SMRs could be a game changer for nuclear power. And this opportunity is hitting at roughly the same time as a massive uptick in demand for electricity. In the U.S. alone, electricity demand is expected to increase 55% between 2020 and 2040. That number doesn't do this shift justice. You need to compare that 55% jump to the fact that demand only rose 9% between 2000 and 2020. This is a huge change and SMRs could easily be a big part of meeting this growing demand. Why is NuScale so volatile? That's the story behind NuScale Power, and it is a good one. But Wall Street has a bad habit of getting a story in its teeth and running with it to the point where the story looks like it can never live up to the stock price. Given the huge rise in NuScale Power's shares, that seems like it may be the case here. And that big 58% drawdown shows how quickly investor sentiment can turn if there's a change in Wall Street's perception of a stock like NuScale. The problem here is that NuScale is losing money and it will likely continue losing money for years to come. It is really just building out its business at this point. To highlight that point, RoPower is lined up to be its first customer but it isn't actually a customer just yet. If RoPower decides not to use NuScale Power's SMRs then NuScale's stock would likely crater. Even if RoPower gives the project the green light, NuScale Power still has to build commercial SMRs. It hasn't actually done that at any scale just yet, so going from zero production to supplying RoPower with six units in a timely fashion is a pretty important test. If NuScale fails the test its shares are, you guessed it, likely to crater. To be fair, inking the first customer is likely to be an important step that will lead to additional customers. But there is a lot up in the air right now even though there is a lot of opportunity. The problem for investors is that the huge price advance in NuScale Power seems to be pricing in a lot of good news that may or may not come to pass. NuScale Power is not appropriate for most investors All in, NuScale Power is likely to interest a very small number of investors at this point. First, you need to be willing to take an aggressive investment approach. Second, you need to believe, strongly, that the best case outcome is going to be the outcome. And, third, you probably need to be willing to invest for a long time period, given the massive price advance over the past year. In other words, the volatility here suggests that most investors will be better off watching from afar. Should you buy stock in NuScale Power right now? Before you buy stock in NuScale Power, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and NuScale Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,783!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,122,682!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends NuScale Power. The Motley Fool has a disclosure policy. Is NuScale Power a buy after recent volatility? was originally published by The Motley Fool
